Normal view MARC view ISBD view

What the infectious disease physician needs to know about pegylated interferon and ribavirin. [Review]

Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007

The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.


English

ISSN: 1058-4838

Subjects--Topical Terms:
*Antiviral Agents/pk [Pharmacokinetics]
*Hepatitis C, Chronic/dt [Drug Therapy]
*Hepatitis C, Chronic/me [Metabolism]
*Interferons/pk [Pharmacokinetics]
*Polyethylene Glycols/pk [Pharmacokinetics]
*Ribavirin/pk [Pharmacokinetics]
Antiviral Agents/ae [Adverse Effects]
Humans
Infectious Disease Medicine
Interferons/ae [Adverse Effects]
Polyethylene Glycols/ae [Adverse Effects]
Ribavirin/ae [Adverse Effects]

Subjects--Geographic Terms:
MedStar Washington Hospital Center

Index Terms--Occupation:
Medicine/Gastroenterology

Index Terms--Function:
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Review